Assessment of Lactobacillus acidophilus (L. acidophilus) therapeutic and prophylactic role in rats experimentally infected with Blastocystis subtype 3 (ST3)

Theodor Bilharz Research Institute

Bibliographic Information

Authors: Alkady S.F.H.; Naggar H.M.A.E.; Thabet H.S.; El-Sayed H.S.; Magdy M.; Fahmy I.A.; Abou-Seri H.M.

Journal: Parasitology Research

Publisher: Springer Science and Business Media Deutschland GmbH

Publication Date: 23 January 2025

Volume / Issue: Volume 124 / Issue 1

Article No.: 11

ISSN: 9320113

DOI: 10.1007/s00436-024-08444-2

Scopus: View on Scopus

PubMed: 39847139

Document Type: Article

Access: All Open Access; Bronze Open Access


Authors and Affiliations

Alkady S.F.H., Medical Parasitology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt; Naggar H.M.A.E., Medical Parasitology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt; Thabet H.S., Medical Parasitology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt; El-Sayed H.S., Dairy Department, National Research Centre, Giza, Egypt; Magdy M., Pathology Department, Theodor Bilharz Research Institute, Giza, Egypt; Fahmy I.A., Medical Parasitology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt; Abou-Seri H.M., Medical Parasitology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt, Faculty of Medicine, Modern University for Technology and Information, Cairo, Egypt


Abstract

Blastocystis, an eukaryote, inhabits the intestinal tract of humans and animals worldwide. Lactobacillus acidophilus (L. acidophilus), a probiotic, has been reported to be effective against blastocystosis. The present study evaluated the therapeutic and prophylactic effectiveness of L. acidophilus compared to metronidazole (MTZ) in rats experimentally infected with Blastocystis subtype 3 (ST3). Four groups of Blastocystis ST3-infected rats received MTZ, L. acidophilus, both MTZ and L. acidophilus, or prophylactic L. acidophilus. Non-infected and infected control groups were included. The effectiveness of treatment and prevention was evaluated using parasitological monitoring, histopathological examination, immunohistochemical staining for TNF-α and IgA expression, and immunological testing for TNF-α and IL-10. In the L. acidophilus-treated group, a 76% reduction in the mean fecal parasitic count and a 67% clearance in the intestinal wash were achieved aligning closely with outcomes observed in the MTZ-treated group. An immunomodulatory impact via upregulation of the anti-inflammatory cytokine IL-10 and downregulation of the pro-inflammatory cytokine TNF-α was demonstrated as well. Combined administration of MTZ and L. acidophilus exhibited superior efficacy with a 99% decrease in the mean fecal parasitic count and a 98% decrease in the intestinal fluid parasitic count. Additionally, the lowest TNF-α and the highest IL-10 serum levels. Prophylactic use of L. acidophilus for 7 days neither prevented infection nor reduced its severity. Furthermore, no significant differences were detected in serum levels of TNF-α and IL-10 following post-prophylaxis and post-treatment with L. acidophilus. Accordingly, L. acidophilus might be recommended as an adjuvant treatment alongside MTZ for improved efficacy against blastocystosis. © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2025.


Keywords

Blastocystis; IgA; IL-10; Immunohistochemistry; Lactobacillus acidophilus; Metronidazole; Subtype 3; TNF-α; Animals; Antiprotozoal Agents; Blastocystis Infections; Disease Models, Animal; Feces; Immunoglobulin A; Interleukin-10; Male; Probiotics; Rats; Treatment Outcome; Tumor Necrosis Factor-alpha; interleukin 10; probiotic agent; tumor necrosis factor; antiprotozoal agent; animal experiment; animal model; Article; blastocystosis; controlled study; down regulation; drug efficacy; feces analysis; histopathology; immunofluorescence; nonhuman; parasite count; protein expression; rat; upregulation; animal; blood; disease model; parasitology; prevention and control


Citation Information

Scopus Citations: 7


For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.

The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.

English Website: https://www.tbri.sci.eg/en/

Arabic Website: https://www.tbri.sci.eg/ar/

Prepared and Uploaded by:

Abdalla F. Abdalla

Electronic Portal Unit

Electronic Portal Unit

Popular Posts

Transcriptome analysis for Schistosoma vector snail’s Oncomelania hupensis exposed to silver nanoparticles

Interpretation of liver stiffness measurement in patients with mixed liver disease etiologies

Multifunctional polycaprolactone-based composite fibers with icariin and glutathione for effective repair of critical-sized bone defects

Holothuria arenicola Extract-Loaded Polycaprolactone Nanocapsules Attenuate Bile Duct Ligation-Induced Acute Liver Injury

Mytilus edulis-mediated green synthesis of selenium nanoparticles with antimicrobial and molluscicidal applications

Microbial levan potentiates hepatic retention and antitumor activity of a PEGylated benzimidazole–curcumin nanocomplex through TLR2–FXR/FGF15-associated immunometabolic remodeling in experimental liver cancer

Variable clinical presentations of pulmonary hydatid cysts: a four-case series from a single center in United Arab Emirates, non-endemic region